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Objective: To investigate the effects of exogenous recombinant human brain natriuretic
peptide (rhBNP) after primary percutaneous coronary intervention (PCI) on non-invasive
hemodynamic in acute myocardial infarction patients with left ventricular failure.
Methods: A number of 96 acute myocardial infarction patients accompanied with heart
failure after PCI hospitalized in the People's Hospital of Sanya during February 2012 to
October 2015 were selected. They were randomly divided into the therapy group (n = 50)
and control group (n = 46). On the basis of routine treatment, patients in the therapy
group were treated with intravenous rhBNP (1.5 mg/kg was intravenous injection with
uniform speed of 3 min, followed by continuous infusion 0.007 5 mg/kg$min for 72 h),
while the control group received conventional treatment. BioZ-2011 non-invasive he-
modynamic real-time monitoring system was used to monitor the hemodynamic pa-
rameters changes and the leaves of plasma pro-BNP, serum creatinine, serum potassium,
serum sodium and urine volume of each group before and after treating for 30 min, 1 h,
3 h, 6 h, 12 h, 24 h, 48 h, 72 h.
Results: Patients in the therapy group showed no effect on heart rate, while after 30 min
of intravenous injection of rhBNP, CO, CI, SV, and SI increased signiﬁcantly and LVET
and TFC reduced at the same time, which had certain effect on blood pressure (SBP/
DBP). Compared with the control group, the therapy group showed a faster and more
effective improvement on hemodynamics.
Conclusions: Acute myocardial infarction patients complicated with left heart failure
after primary PCI can signiﬁcantly improve hemodynamics by treating with rhBNP.1. Introduction
Acute myocardial infarction (AMI) has been a disease
threatening human health seriously, because infarction can
cause necrosis of a large number of myocardial cells, stunned
myocardium, apoptosis, severe deletion of myocardial cells,
which can lead to heart dysfunction directly, initiateneuroendocrine-activated myocardial remodeling of cell and
heart failure. Percutaneous coronary intervention (PCI) is an
effective method to save ischemic myocardium and protect
heart function, which decreases the mortality rate of AMI pa-
tients distinctly. However, heart failure still occurs in AMI
patients after they have been treated by PCI. Recombinant
human brain natriuretic peptide (rhBNP) possesses the same
amino acid sequence and mode of action with endogenous
peptides-brain natriuretic peptide (BNP) secreted by ventricular
myocytes. RhBNP is conductive to even blood vessels dilation,
diuresis and sodium excretion, reduction of the pre-load and
pro-load of heart and the correction of blood stream dynamics
disorder for heart failure patients. Meanwhile, it can inhibit the
activation of neuroendocrine and improve ventricle
remodeling.
From February 2012 to October 2015, bioZ-2011 non-
invasive hemodynamic real-time monitoring system wasrticle under the CC BY-NC-ND license (http://
Table 1
General clinical materials of patients in the two groups.
Terms Therapy group Control group P
Gender (male/female) 28/22 24/22 0.710
Age (year) 66.72 ± 6.33 67.83 ± 4.90 0.340
Hypertension (n; %) 16 (32%) 20 (43%) 0.410
Hyperlipidemia case (n; %) 24 (48%) 21 (46%) 0.820
Diabetes (n; %) 16 (32%) 12 (26%) 0.530
Smoking (n; %) 12 (24%) 10 (22%) 0.790
Heart function classiﬁcation
Killip II (n; %) 13 (26%) 12 (26.1%) 0.994
Killip III (n; %) 29 (58%) 27 (58.7%) –
Killip IV (n; %) 8 (16%) 7 (15.2%) –
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gate the effects of rhBNP after PCI on non-invasive hemody-
namic in acute myocardial infarction patients with left
ventricular failure.
2. Materials and methods
2.1. Clinical materials
A number of 96 acute myocardial infarction patients
accompanied with heart failure after PCI who were hospitalized
in the Department of Cardiology of the People's Hospital of
Sanya during February 2012 to October 2015 were selected.
Among them, 52 cases were males and 44 cases were females
with ages ranging from (53.5 ± 8.4) years. The inclusion
criteria include: 1. Ages between (30–75) years old without
gender limitation; 2. The diagnose standard of AMI was in
accordance with the clinical implications of the third universal
deﬁnition of myocardial infarction [1]; 3. The indication of PCI
was conducted on the basis of the internationally existed
standards [2]; 4. The Killip classiﬁcation of acute myocardial
infarction patients with left ventricular failure after PCI was
II–IV. The exclusion criteria were: 1. Patients with
cardiogenic shock or a systolic pressure of 90 mmHg after
treating with booster drugs; 2. Patients treated with monarkite
or contraindicant vein vasodilator; 3. Patients accompanied
with other diseases, such as malignant tumors, infectious
diseases, mental disorders and so on and also patients with
incomplete materials.
2.2. Treatment and monitoring methods
Those selected patients were randomly divided into the
control group (n = 46) and the therapy group (n = 50). Patients in
the control group were given routine antithrombotic therapy,
coronary dilatation, diuresis and cardiac load reduction, ACEI or
ARB, b receptor blocker, lipid regulation, plaque stabilization,
etc, while patients in the therapy group, base on the routine
treatment, were treated with rhBNP (trade name: Natriuretic
peptide, 0.5 mg/piece) (Tibet Rhodiola Pharmaceutical Holding
Co.) (1.5 mg/kg was intravenously injected with uniform speed
in the ﬁrst three minutes, followed by continuous infusion of
0.007 5 mg/kg$min for 72 h).
In this study, BioZ-2011 non-invasive hemodynamic moni-
toring instrument was used and operated in the light of the in-
structions carefully and faithfully to determine the hemodynamic
parameters at 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, 72 h before
and after treatment which included heart rate, blood pressure,
stroke volume, cardiac index, peripheral vascular resistance, etc,
and the plasma NT-proBNP level, renal function, electrolyte and
urine volume of the two groups before and after treatment were
also monitored.
2.3. Statistical methods
All data of the selected patients were collected by well-
trained professional doctors before patients were grouped. The
main data included non-invasive hemodynamic monitoring,
blood samples, urine samples and so on. Professional statisticssoftware SPSS21.0 was applied to deal with statistics. Mea-
surement data of the two groups were tested by t-test. Com-
parison of means of more than two groups was analyzed by One-
way ANOVA. Comparison of enumeration data between groups
was tested by Chi-square test. Differences showed statistical
signiﬁcance when P < 0.05.
3. Results
3.1. General clinical materials
The clinical materials of those 50 and 46 cases in the two
groups including gender, age, histories of hypertension, dia-
betes, hyperlipidemia, smoking, heart function classiﬁcation and
so on showed no statistical signiﬁcance (P > 0.05), which
indicated a good balance and comparability (Table 1).
3.2. Hemodynamic parameters
Data of the hemodynamic parameters at different time points
of the two groups were shown in Tables 2–4.
The results showed that the heart rate (HR) of patients in the
therapy group was not inﬂuenced. After treating for one hour,
their blood pressure was declined; the cardiac output (CO),
cardiac index (CI), stroke volume (SV) and stroke index (SI)
increased obviously after treating for 0.5 h; the LVET could
extended after treating for 3 h; TFC could be reduced after 6 h.
However, as for the control group, the clinical effect worked
relatively late, which implied that the therapy group had a faster
and more effective improvement effect of hemodynamics as
compared with the control group.
3.3. NT-proBNP, urine volume and renal function index
The results revealed that after treating 72 h the serum
creatinine level of patients in the therapy group decreased,
while their blood potassium and blood sodium showed no
signiﬁcant changes. In addition, their urine volume increased
evidently and the NT-proBNP improved apparently. The
improvement of renal function, urine volume and NT-proBNP
of the therapy group was better than that of the control group
(Tables 5 and 6).
Table 4
Comparison of SI, LVET and TFC monitored at different time points of the two groups.
Time (h) SI LVET TFC
Therapy group Control group Therapy group Control group Therapy group Control group
0 33.94 ± 5.72 32.42 ± 5.96 289.52 ± 14.66 288.70 ± 14.54 28.60 ± 2.51 28.98 ± 2.52
0.5 37.74 ± 4.72*# 33.59 ± 6.07 287.80 ± 13.82 288.43 ± 13.62 28.38 ± 3.50 29.02 ± 2.66
1 38.24 ± 4.72*# 34.01 ± 5.92 287.86 ± 13.78 288.09 ± 11.62 28.16 ± 3.27 28.96 ± 2.60
6 39.32 ± 5.03*# 36.06 ± 5.90# 286.28 ± 14.18*# 288.00 ± 12.13 27.44 ± 3.30*# 28.72 ± 3.17
12 39.82 ± 4.78*# 37.39 ± 5.90# 285.80 ± 13.32*# 287.83 ± 12.25 27.38 ± 3.20*# 28.61 ± 2.82
24 40.26 ± 5.50*# 37.76 ± 5.87# 284.86 ± 12.78# 285.83 ± 12.25# 27.24 ± 3.16# 27.37 ± 3.07#
48 41.32 ± 4.63*# 38.13 ± 5.80# 284.06 ± 14.20# 284.35 ± 12.75# 26.16 ± 3.52# 27.43 ± 2.77#
72 41.82 ± 4.58*# 38.33 ± 5.80# 283.20 ± 14.44# 284.20 ± 12.52# 26.04 ± 3.21# 27.48 ± 2.54#
*P < 0.05 compared with the control group; #P < 0.05 compared with level before treatment.
Table 5
Comparison of serum creatinine, blood potassium and blood sodium of the two groups before and after treating for 72 h.
Groups Serum creatinine (mmol/L) Blood potassium (mmol/L) Blood sodium (mmol/L)
Therapy group Control group Therapy group Control group Therapy group Control group
Before treatment 89.56 ± 9.21 88.07 ± 11.90 4.02 ± 0.27 4.06 ± 0.31 136.57 ± 7.86 138.74 ± 7.91
After treatment 80.26 ± 7.76*# 87.70 ± 10.31 4.10 ± 0.29 4.15 ± 0.33 138.35 ± 9.22 143.57 ± 7.76
*P < 0.05 compared with the control group; #P < 0.05 compared with level before treatment.
Table 6
Comparison of urine volume and plasma NT-proBNP level of the two groups before and after treating for 72 h.
Groups Urine volume (mL/d) NT-proBNP (pg/mL)
Therapy group Control group Therapy group Control group
Before treatment 1100.6 ± 80.17 1185.17 ± 64.12 4394.00 ± 861.75 4239.13 ± 893.80
After treatment 1680.80 ± 262.20*# 1290.48 ± 103.69# 782.00 ± 338.09*# 2585.87 ± 455.30#
*Compared with the control group, P < 0.05; #P < 0.05 compared with level before treatment.
Table 3
Comparison of CO, CI and SV monitored at different time points of the two groups.
Time (h) CO CI SV
Therapy group Control group Therapy group Control group Therapy group Control group
0 4.51 ± 0.55 4.52 ± 0.52 2.44 ± 0.29 2.46 ± 0.28 58.10 ± 8.06 57.09 ± 6.59
0.5 4.74 ± 0.51*# 4.53 ± 0.51 2.62 ± 0.20*# 2.51 ± 0.28 62.78 ± 6.58*# 59.09 ± 7.42
1 4.77 ± 0.49*# 4.54 ± 0.52 2.64 ± 0.33*# 2.52 ± 0.26 63.28 ± 6.86*# 59.09 ± 7.42
3 4.80 ± 0.44*# 4.57 ± 0.50 2.69 ± 0.36*# 2.53 ± 0.25 64.04 ± 6.39*# 59.63 ± 7.58
6 4.84 ± 0.44*# 4.68 ± 0.47# 2.75 ± 0.29*# 2.55 ± 0.25 65.06 ± 5.85*# 61.07 ± 7.49#
12 4.86 ± 0.44*# 4.69 ± 0.47# 2.80 ± 0.33*# 2.60 ± 0.23# 65.98 ± 5.64*# 61.11 ± 7.48#
24 4.88 ± 0.43*# 4.70 ± 0.46# 2.85 ± 0.34*# 2.61 ± 0.23# 66.40 ± 5.36*# 62.17 ± 7.55#
48 4.87 ± 0.43*# 4.71 ± 0.48# 2.90 ± 0.35*# 2.68 ± 0.22# 67.38 ± 5.30*# 62.52 ± 6.55#
72 4.91 ± 0.43*# 4.75 ± 0.42# 2.96 ± 0.37*# 2.72 ± 0.21# 67.90 ± 5.33*# 63.63 ± 6.69#
*P < 0.05 compared with the control group; #P < 0.05 compared with level before treatment.
Table 2
Comparison of HR, SBP and DBP monitored at different time points of the two groups.
Time (h) HR (time/min) SBP (mmHg) DBP (mmHg)
Therapy group Control group Therapy group Control group Therapy group Control group
0 64.56 ± 3.73 65.98 ± 5.29 125.10 ± 21.39 129.78 ± 22.26 82.40 ± 20.91 87.87 ± 19.70
0.5 66.24 ± 4.65 67.78 ± 5.94 118.98 ± 11.88 125.41 ± 14.32 79.84 ± 13.40 80.00 ± 11.23
1 66.78 ± 5.99 68.59 ± 5.95 110.50 ± 10.70*# 125.80 ± 10.24 74.16 ± 10.25*# 81.61 ± 10.71
3 67.08 ± 4.84 68.22 ± 5.48 110.64 ± 12.32*# 120.67 ± 12.83 70.00 ± 14.31*# 80.26 ± 10.76
6 68.12 ± 5.29 69.09 ± 5.72 109.88 ± 10.88*# 118.20 ± 11.62 71.14 ± 12.21*# 79.61 ± 9.30
12 66.46 ± 4.18 67.93 ± 5.20 107.14 ± 11.15*# 117.20 ± 12.63 70.06 ± 11.90*# 75.78 ± 11.57
24 66.74 ± 4.24 68.07 ± 4.65 108.16 ± 11.17*# 120.48 ± 10.40 72.18 ± 9.04*# 75.61 ± 10.21
48 67.62 ± 3.49 68.07 ± 4.65 110.46 ± 9.69*# 121.22 ± 11.65 72.48 ± 7.64# 73.37 ± 9.49#
72 67.50 ± 3.27 67.54 ± 4.88 112.14 ± 9.12* 119.24 ± 13.03 74.80 ± 7.38# 72.11 ± 8.85#
*P < 0.05 compared with the control group; #P < 0.05 compared with level before treatment.
Xi-Min He et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(8): 791–795 793
Xi-Min He et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(8): 791–7957944. Discussion
AMI is a common disease which harms human health badly.
AMI joint with heart failure still remains to be an important cause
and one of the most severe complications for patients’ death. The
main reason is that in the pro-AMI period the activated neuro-
endocrine system, including RAAS, stomodeal nervous system,
netriuretic peptide system and so on, was not inhibited effectively.
High level of neuroendocrine hormone made the cardiovascular
system in a state of over-stress for a long time, prompted cardiac
remodeling, resulted in excessive ﬁbrosis for cardiac muscular
tissues, destroyed myocardial ﬁbers sequence, damaged the
normal cardiac pacemaker conduction system, induced myocar-
dial ischemia and abnormal heart rate, smashed the harmony of
cardiac contractile function, triggered pump failure and ﬁnally
increased heart events while treating AMI.
Brain natriuretic peptide is a kind of endogenous polypeptide
hormones secreted by ventricular myocytes. Its secretion level is
connected with the severity of the cardiac volume load and
pressure load, which plays an important role in the protective
compensation mechanism of circulation dynamics volume and
pressure control [3]. rhBNP is a recombinant human brain
natriuretie peptide compounded by DNA technology. It has
the same 32 amino acid sequences with the ventricular
myocytes-produced endogenous BNP and it can also imitate
the effect of endogenous brain natriuretic peptide, such as
natriuresis, diuresis, reduction of the activities of angiotasis,
antagonism RAAS and stomodeal nervous system, correction of
the hemodynamic disorder of heart failure patients, etc. FDA has
been allowed to use in acute decompensated heart failure since
2001, which is the only approved drug used in the ﬁeld of
treating heart failure during the past 30 years. At present, it has
been recommended by ACCF/AHA Guideline for the Manage-
ment of Heart Failure, Focused Update: ACCF/AHA Guidelines
for the Diagnosis and Management of Heart Failure in Adults
and 2014 Guideline for the diagnose and treatment of heart
failure in China [4–6].
rhBNP can not only improve hemodynamic disorder, natri-
uresis and diuresis without affecting serum potassium and
creatinine, but also ﬁght against the over-activation of the
neuroendocrine system, relieve inﬂammatory responses,
improve ventricular remodeling and protect hearts comprehen-
sively [7]. Jing Sun et al. [8] stated that patients with AMI should
be treated with rhBNP after PCI as soon as possible, since it can
obviously inhibit the over-activation of the neuroendocrine
system, alleviate the local inﬂammatory responses of myocardial
cells, ischemia reperfusion injury and cardiac load and interdict
the initiating factors of ventricular remodeling after myocardial
infarction. Besides, rhBNP can inhibit the physiological action
of the activity of cardiac sympathetic nerve directly by
decreasing the plasma aldosterone level and the secretion of
norepinephrine [9]. Michaels [10] measured the intracoronary
rheography before and after using rhBNP by intracoronary
Doppler. After using brain natriuretic peptide, the diameter of
coronary artery expanded 15%, the coronary resistance
reduced by 23%, the intracoronary blood ﬂow volume
increased by 35% and the coronary oxygen consumption
reduced by 8%. rhBNP can improve the blood supply of
coronary artery effectively, lighten myocardial oxygen
consumption and adjust the resistance of overall circulation
and coronary circulation alternatively so as to integrate the
volume load and pressure load of the whole body.The results of this study showed that the hemodynamic in-
dexes of AMI patients accompanied with heart failure after PCI
treatment in the therapy group have been improved efﬁca-
ciously. Compared with the control group, the therapy group
showed a faster and more effective improvement effect on he-
modynamics. After those patients were treated for 0.5 h, the CO/
CI and SV/SI were improved obviously as compared with those
before treatment. LVET and TFC also decreased evidently,
which indicated that rhBNP could improve the hemodynamics
quickly for AMI patients complicated with left heart failure after
PCI treatment. Meanwhile, the urine volume of patients in the
therapy group increased signiﬁcantly after treatment and their
plasma NT-proBNP decreased obviously, but the serum potas-
sium and blood natrium remained unaffected, which conﬁrmed
that rhBNP played a certain protective role for the renal function
for patients. A meta analysis demonstrated that rhBNP has sig-
niﬁcant positive impact on the improvement of hemodynamic
parameters and risks of the increases of creatinine and urea ni-
trogen of rhBNP have not been found yet, which is consistent
with the results of this study [11].
That study result pointed out that the earlier application of
rhBNP combined with non-invasive hemodynamic monitoring
system can improve the hemodynamic parameters of AMI pa-
tients accompanied with heart failure after PCI without the
expense of fastening heart rate and increasing cardiac work ef-
ﬁciency and myocardial oxygen consumption. Besides, in the
treating process, side effects such as electrolyte disturbances,
unstable blood pressure have not been found after the diuresis
and vasodilatory effects, which indicated that the treating
methods possesses excellent security and physiological tolerance
and it can be widely recommended and used in clinic.
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